Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.
Morieri ML, Candido R, Frontoni S, Disoteo O, Solini A, Fadini GP; PIONEERING EXPERIENCE study group. Morieri ML, et al. Among authors: candido r. Diabetes Ther. 2023 Dec;14(12):2159-2172. doi: 10.1007/s13300-023-01490-6. Epub 2023 Oct 18. Diabetes Ther. 2023. PMID: 37848758 Free PMC article.
The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care.
Russo G, Di Bartolo P, Candido R, Lucisano G, Manicardi V, Giandalia A, Nicolucci A, Rocca A, Rossi MC, Di Cianni G; AMD Annals Study Group. Russo G, et al. Among authors: candido r. Diabetes Res Clin Pract. 2023 May;199:110672. doi: 10.1016/j.diabres.2023.110672. Epub 2023 Apr 19. Diabetes Res Clin Pract. 2023. PMID: 37084893 Free article.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials.
Mannucci E, Gallo M, Pintaudi B, Targher G, Candido R, Giaccari A, Monami M; SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Mannucci E, et al. Among authors: candido r. Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):511-514. doi: 10.1016/j.numecd.2021.10.010. Epub 2021 Nov 1. Nutr Metab Cardiovasc Dis. 2022. PMID: 34893404
Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.
Monami M, Candido R, Pintaudi B, Targher G, Mannucci E; SID-AMD joint Panel for Italian Guidelines on Treatment of Type 2 Diabetes. Monami M, et al. Among authors: candido r. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):699-704. doi: 10.1016/j.numecd.2020.11.031. Epub 2020 Dec 10. Nutr Metab Cardiovasc Dis. 2021. PMID: 33549430
2023 update on Italian guidelines for the treatment of type 2 diabetes.
Mannucci E, Candido R, Monache LD, Gallo M, Giaccari A, Masini ML, Mazzone A, Medea G, Pintaudi B, Targher G, Trento M, Turchetti G, Lorenzoni V, Monami M; for Società Italiana di Diabetologia (SID) and Associazione Medici Diabetologi (AMD). Mannucci E, et al. Among authors: candido r. Acta Diabetol. 2023 Aug;60(8):1119-1151. doi: 10.1007/s00592-023-02107-x. Epub 2023 May 26. Acta Diabetol. 2023. PMID: 37233852 Free PMC article. No abstract available.
190 results